Therapeutic area intelligence for Erectile Dysfunction with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

L-Citrulline →

Teva →

Assets

Tadalafil →

Vardenafil Hydrochloride →

Recent signals(2)

RegulatoryAugust 15, 2026

Teva Pharmaceuticals receives AP status for Vardenafil Hydrochloride ANDA091347

Teva Pharmaceuticals has received Abbreviated Approval (AP) status for its ANDA091347 application for Vardenafil Hydrochloride, a treatment for erectile dysfunction.

ClinicalAugust 1, 2026

Trial of L-Citrulline and Tadalafil for Erectile Dysfunction Shows Potential Combination Benefits

A randomized trial is comparing L-citrulline, tadalafil, and their combination in men with mild to moderate erectile dysfunction.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.